Ophthalmology Times: November 1, 2021

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

Successful treatment options can offer hope for patients with inherited disease.

Investigators believe the therapy could prove to be an option for the treatment of other retinopathies.

Investigators find that youth show altered ocular movements, reduced amplitude of accommodation.

The unique MOA may deliver a synergistic effect when prescribed post-surgically.

An experience at the grocery store serves as a reminder of the importance of fundraising for eye research.

Pilot study tests the technology to obtain remote fundus imaging of patients.

Staying current on phaco technology can help surgeons provide better outcomes.

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).